GILD

Gilead Sciences
D

GILD

Arincen87/100B
166.870
USD
-0.73
(-0.44%)
Pre Open·168.040USD+1.170(+0.70%)
Last updated: · Delayed 15 min

Gilead Sciences cash on hand 1990–2026

Gilead Sciences had 6.44B USD in cash and short-term investments on 30 September 2026, down 12.4% on a year before. At the end of fiscal year 2025 it had 9.61B USD.

Last updated 9 Nov 2026 · Next report 9 Feb 2027

Cash on hand

Growth

Fiscal yearPeriod endingCash on handGrowthTotal debtNet cash
Latest quarter30 Sept 20266.44B-12.41%26.23B-19.79B
FY202531 Dec 20259.61B-16.90%24.94B-15.32B
FY202431 Dec 202411.57B+59.25%26.71B-15.14B
FY202331 Dec 20237.26B+13.77%24.99B-17.72B
FY202231 Dec 20226.39B-2.07%25.23B-18.85B
FY202131 Dec 20216.52B-11.99%26.70B-20.18B
FY202031 Dec 20207.41B-69.58%31.40B-23.99B
FY201931 Dec 201924.35B-19.07%24.59B-241.00M
FY201831 Dec 201830.09B+17.95%27.32B2.77B
FY201731 Dec 201725.51B+114.46%33.54B-8.03B
FY201631 Dec 201611.90B-18.57%26.35B-14.45B
FY201531 Dec 201514.61B+44.22%22.06B-7.45B
FY201431 Dec 201410.13B+375.05%12.40B-2.28B
FY201331 Dec 20132.13B+14.49%6.64B-4.50B
FY201231 Dec 20121.86B-81.19%8.22B-6.36B
FY201131 Dec 20119.90B+371.74%7.61B2.29B
FY201031 Dec 20102.10B+26.66%3.48B-1.39B
FY200931 Dec 20091.66B-7.43%1.25B402.98M
FY200831 Dec 20081.79B+52.74%1.16B629.82M
FY200731 Dec 20071.17B+25.10%1.31B-139.91M
FY200631 Dec 2006936.85M-59.46%1.41B-473.74M
FY200531 Dec 20052.31B+84.29%300.86M2.01B
FY200431 Dec 20041.25B+77.37%415.00K1.25B
FY200331 Dec 2003707.00M-24.98%345.46M361.54M
FY200231 Dec 2002942.37M+61.68%595.47M346.91M
FY200131 Dec 2001582.85M+13.64%251.88M330.97M
FY200031 Dec 2000512.88M+74.21%255.27M257.61M
FY199931 Dec 1999294.39M+191.19%87.98M206.42M
FY199831 Dec 1998101.10M+215.94%101.50M-400.00K
FY199731 Dec 199732.00M-75.76%3.20M28.80M
FY199631 Dec 1996132.00M+381.75%6.50M125.50M
FY199531 Dec 199527.40M-9.87%6.40M21.00M
FY199431 Dec 199430.40M+1,347.62%8.40M22.00M
FY199231 Dec 19922.10M-97.61%1.80M300.00K
FY199131 Dec 199187.90M+753.40%1.00M86.90M
FY199031 Dec 199010.30M—800.00K9.50M

Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.

See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Total debt,Free cash flow,Stock buybacks,Balance sheet

Common questions about Gilead Sciences's cash

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.